传染病信息

[1]Rinella ME.Nonalcoholic fatty liver disease:a systematic review[J].JAMA,2015,313(22):2263-2273.DOI:10.1001/jama.2015.5370.

[2]Diehl AM,Day C.Cause,pathogenesis,and treatment of nonalcoholic steatohepatitis[J].N Engl J Med,2017,377(21):2063-2073.DOI:10.1056/NEJMra1503519.

[3]Wang FS,Fan JG,Zhang Z,et al.The global burden of liver disease:the major impact of China[J].Hepatology,2014,60(6):2099-2108.DOI:10.1002/hep.27406.

[4]Fan JG,Kim SU,Wong VW.New trends on obesity and NAFLDin Asia[J].J Hepatol,2017,67(4):862-873.DOI:10.1016/j.jhep.2017.06.003.

[5]Wang MM,Wang GS,Shen F,et al.Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors[J].Dig Dis Sci,2014,59(10):2571-2579.DOI:10.1007/s10620-014-3180-9.

[6]Fan JG,Jia JD,Li YM,et al.Guidelines for the diagnosis and management of nonalcoholic fatty liver disease:update2010:(published in Chinese on Chinese Journal of Hepatology 2010;18:163-166)[J].J Dig Dis,2011,12(1):38-44.DOI:10.1111/j.1751-2980.2010.00476.x.

[7]Review Team,LaBrecque DR,Abbas Z,et al.World Gastroenterology Organisation global guideline:Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J].J Clin Gastroenterol,2014,48(6):467-473.DOI:10.1097/MCG.0000000000000116.

[8]Wong VW,Chan WK,Chitturi S,et al.Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease Guidelines 2017-Part1:Definition,risk factors and assessment[J].J Gastroenterol Hepatol,2018,33(1):70-85.DOI:10.1111/jgh.13857.

[9]Chalasani N,Younossi Z,Lavine JE,et al.The diagnosis and management of nonalcoholic fatty liver disease:practice guidance from the American Association for the Study of Liver Diseases[J].Hepatology,2018,67(1):328-357.DOI:10.1002/hep.29367.

[11]Younossi ZM,Koenig AB,Abdelatif D,et al.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence,incidence,and outcomes[J].Hepatology,2016,64(1):73-84.DOI:10.1002/hep.28431.

[12]Zhu JZ,Zhou QY,Wang YM,et al.Prevalence of fatty liver disease and the economy in China:A systematic review[J].World JGastroenterol,2015,21(18):5695-5706.DOI:10.3748/wjg.v21.i18.5695.

[13]Wong VW,Wong GL,Yeung DK,et al.Incidence of non-alcoholic fatty liver disease in Hong Kong:a population study with paired proton-magnetic resonance spectroscopy[J].J Hepatol,2015,62(1):182-189.DOI:10.1016/j.jhep.2014.08.041.

[14]Xu C,Yu C,Ma H,et al.Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population:the Zhejiang Zhenhai Study[J].Am J Gastroenterol,2013,108(8):1299-1304.DOI:10.1038/ajg.2013.104.

[15]Kwok R,Choi KC,Wong GL,et al.Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements:a prospective cohort study[J].Gut,2016,65(8):1359-1368.DOI:10.1136/gutjnl-2015-309265.

[16]Zhang RN,Zheng RD,Mi YQ,et al.APOC3 rs2070666 is associated with the hepatic steatosis independently of PNPLA3 rs738409 in Chinese Han patients with nonalcoholic fatty liver diseases[J].Dig Dis Sci,2016,61(8):2284-2293.DOI:10.1007/s10620-016-4120-4127.

[17]Xu L,Ma H,Miao M,et al.Impact of subclinical hypothyroidism on the development of non-alcoholic fatty liver disease:a prospective case-control study[J].J Hepatol,2012,57(5):1153-1154.DOI:10.1016/j.jhep.2012.05.025.

[18]Xu C,Yu C,Xu L,et al.High serum uric acid increases the risk for nonalcoholic Fatty liver disease:a prospective observational study[J].PLoS One,2010,5(7):e11578.DOI:10.1371/journal.pone.0011578.

[19]Ma H,Xu C,Xu L,et al.Independent association of HbA1c and nonalcoholic fatty liver disease in an elderly Chinese population[J].BMC Gastroenterol,2013,13:3.DOI:10.1186/1471-230X-13-3.

[20]Xu C,Wan X,Xu L,et al.Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia:One stone hits two birds[J].JHepatol,2015,62(6):1412-1419.DOI:10.1016/j.jhep.2015.01.019.

[21]Dulai PS,Singh S,Patel J,et al.Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease:Systematic review and meta-analysis[J].Hepatology,2017,65(5):1557-1565.DOI:10.1002/hep.29085.

[22]Leung JC,Loong TC,Wei JL,et al.Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients[J].Hepatology,2017,65(1):54-64.DOI:10.1002/hep.28697.

[23]Wang Y,Wang B,Shen F,et al.Body mass index and risk of primary liver cancer:a meta-analysis of prospective studies[J].Oncologist,2012,17(11):1461-1468.DOI:10.1634/theoncologist.2012-0066.

[24]Wong VW,Wong GL,Yeung JC,et al.Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram:A prospective cohort study[J].Hepatology,2016,63(3):754-763.DOI:10.1002/hep.28253.

[25]Ballestri S,Zona S,Targher G,et al.Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type2 diabetes and metabolic syndrome.Evidence from a systematic review and meta-analysis[J].J Gastroenterol Hepatol,2016,31(5):936-944.DOI:10.1111/jgh.13264.

[26]Chen GY,Cao HX,Li F,et al.New-risk-scoring system including non-alcoholic fatty liver disease for predicting incident type 2diabetes in East China:Shanghai Baosteel Cohort[J].J Diabetes Investig,2016,7(2):206-211.DOI:10.1111/jdi.12395.

[27]Wu S,Wu F,Ding Y,et al.Association of non-alcoholic fatty liver disease with major adverse cardiovascular events:A systematic review and meta-analysis[J].Sci Rep,2016,6:33386.DOI:10.1038/srep33386.

[28]Targher G,Byrne CD,Lonardo A,et al.Non-alcoholic fatty liver disease and risk of incident cardiovascular disease:A metaanalysis[J].J Hepatol,2016,65(3):589-600.DOI:10.1016/j.jhep.2016.05.013.

[29]Wu R,Hou F,Wang X,et al.Nonalcoholic fatty liver disease and coronary artery calcification in a northern Chinese population:a cross sectional study[J].Sci Rep,2017,7(1):9933.DOI:10.1038/s41598-017-09851-5.

[30]Musso G,Gambino R,Tabibian JH,et al.Association of nonalcoholic fatty liver disease with chronic kidney disease:a systematic review and meta-analysis[J].PLoS Med,2014,11(7):e1001680.DOI:10.1371/journal.pmed.1001680.

[31]Zeng J,Sun C,Sun WL,et al.Association between non-invasively diagnosed hepatic steatosis and chronic kidney disease in Chinese adults at a health check-up[J].J Dig Dis,2017,18(4):229-236.DOI:10.1111/1751-2980.12465.

[33]Chitturi S,Wong VW,Chan WK,et al.The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part2:Management and special groups[J].J Gastroenterol Hepatol,2018,33(1):86-98.DOI:10.1111/jgh.13856.

[34]European Association for Study of Liver,Asociacion Latinoamericana para el Estudio del Higado.EASL-ALEH Clinical Practice Guidelines:Non-invasive tests for evaluation of liver disease severity and prognosis[J].J Hepatol,2015,63(1):237-264.DOI:10.1016/j.jhep.2015.04.006.

[35]Xu L,Lu W,Li P,et al.A comparison of hepatic steatosis index,controlled attenuation parameter and ultrasound as noninvasive diagnostic tools for steatosis in chronic hepatitis B[J].Dig Liver Dis,2017,49(8):910-917.DOI:10.1016/j.dld.2017.03.013.

[36]Shen F,Zheng RD,Mi YQ,et al.Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients[J].World J Gastroenterol,2014,20(16):4702-4711.DOI:10.3748/wjg.v20.i16.4702.

[37]Shen F,Zheng RD,Shi JP,et al.Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease[J].Liver Int,2015,35(11):2392-2400.DOI:10.1111/liv.12809.

[38]Karlas T,Petroff D,Sasso M,et al.Individual patient data metaanalysis of controlled attenuation parameter(CAP)technology for assessing steatosis[J].J Hepatol,2017,66(5):1022-1030.DOI:10.1016/j.jhep.2016.12.022.

[39]沈峰,郑瑞丹,宓余强,等.细胞角蛋白-18联合受控衰减参数二步法无创鉴别非酒精性脂肪性肝炎的临床研究[J].中华肝脏病杂志,2016,24(6):429-434.DOI:10.3760/cma.j.issn.1007-3418.2016.06.007.Shen F,Zheng RD,Mi YQ,et al.Value of a two-step approach with cytokeratin-18 and controlled attenuation parameter in noninvasive differential diagnosis of nonalcoholic steatohepatitis[J].Chin J Hepatol,2016,24(6):429-434.DOI:10.3760/cma.j.is sn.1007-3418.2016.06.007.

[40]Bedossa P,FLIP Pathology Consortium.Utility and appropriateness of the fatty liver inhibition of progression(FLIP)algorithm and steatosis,activity,and fibrosis(SAF)score in the evaluation of biopsies of nonalcoholic fatty liver disease[J].Hepatology,2014,60(2):565-575.DOI:10.1002/hep.27173.

[41]Xun YH,Fan JG,Zang GQ,et al.Suboptimal performance of simple noninvasive tests for advanced fibrosis in Chinese patients with nonalcoholic fatty liver disease[J].J Dig Dis,2012,13(11):588-595.DOI:10.1111/j.1751-2980.2012.00631.x.

[42]Petta S,Wong VW,CammàC,et al.Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values[J].Hepatology,2017,65(4):1145-1155.DOI:10.1002/hep.28843.

[43]曾静,孙婉璐,陈光榆,等.FibroTouch与Fibro Scan肝脏硬度和脂肪定量检测效能的比较[J].中华肝脏病杂志,2016,24(9):652-658.DOI:10.3760/cma.j.issn.1007-3418.2016.09.004.Zeng J,Sun WL,Chen GY,et al.Efficiency of FibroScan and FibroTouch in liver stiffness measurement and fat quantification:a comparative analysis[J].Chin J Hepatol,2016,24(9):652-658.DOI:10.3760/cma.j.issn.1007-3418.2016.09.004.

[44]Singh S,Muir AJ,Dieterich DT,et al.American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases[J].Gastroenterology,2017,152(6):1544-1577.DOI:10.1053/j.gastro.2017.03.016.

[45]Yu C,Xu C,Xu L,et al.Serum proteomic analysis revealed diagnostic value of hemoglobin for nonalcoholic fatty liver disease[J].J Hepatol,2012,56(1):241-247.DOI:10.1016/j.jhep.2011.05.027.

[46]Nascimbeni F,Pais R,Bellentani S,et al.From NAFLD in clinical practice to answers from guidelines[J].J Hepatol,2013,59(4):859-871.DOI:10.1016/j.jhep.2013.05.044.

[47]Romero-Gómez M,Zelber-Sagi S,Trenell M.Treatment of NAFLDwith diet,physical activity and exercise[J].J Hepatol,2017,67(4):829-846.DOI:10.1016/j.jhep.2017.05.016.

[48]Wong VW,Chan RS,Wong GL,et al.Community-based lifestyle modification programme for non-alcoholic fatty liver disease:a randomized controlled trial[J].J Hepatol,2013,59(3):536-542.DOI:10.1016/j.jhep.2013.04.013.

[49]Fan JG,Cao HX.Role of diet and nutritional management in nonalcoholic fatty liver disease[J].J Gastroenterol Hepatol,2013,28Suppl 4:81-87.DOI:10.1111/jgh.12244.

[50]Zhang HJ,He J,Pan LL,et al.Effects of Moderate and Vigorous Exercise on Nonalcoholic Fatty Liver Disease:A Randomized Clinical Trial[J].JAMA Intern Med,2016,176(8):1074-1082.DOI:10.1001/jamainternmed.2016.3202.

[51]Zhang HJ,Pan LL,Ma ZM,et al.Long-term effect of exercise on improving fatty liver and cardiovascular risk factors in obese adults:A 1-year follow-up study[J].Diabetes Obes Metab,2017,19(2):284-289.DOI:10.1111/dom.12809.

[52]Argo CK,Patrie JT,Lackner C,et al.Effects of n-3 fish oil on metabolic and histological parameters in NASH:a doubleblind,randomized,placebo-controlled trial[J].J Hepatol,2015,62(1):190-197.DOI:10.1016/j.jhep.2014.08.036.

[53]Athyros VG,Tziomalos K,Gossios TD,et al.Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation(GREACE)Study:a post-hoc analysis[J].Lancet,2010,376(9756):1916-1922.DOI:10.1016/S0140-6736(10)61272-X.

[54]Bril F,Portillo Sanchez P,Lomonaco R,et al.Liver safety of statins in prediabetes or T2DM and nonalcoholic steatohepatitis:post hoc analysis of a randomized trial[J].J Clin Endocrinol Metab,2017,102(8):2950-2961.DOI:10.1210/jc.2017-00867.

[55]Armstrong MJ,Gaunt P,Aithal GP,et al.Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis(LEAN):a multicentre,double-blind,randomised,placebo-controlled phase 2study[J].Lancet,2016,387(10019):679-690.DOI:10.1016/S0140-6736(15)00803-X.

[56]Cusi K,Orsak B,Bril F,et al.Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2diabetes mellitus:a randomized trial[J].Ann Intern Med,2016,165(5):305-315.DOI:10.7326/M15-1774.

[57]Brito JP,Montori VM,Davis AM.Metabolic surgery in the treatment algorithm for type 2 diabetes:a joint statement by international diabetes organizations[J].JAMA,2017,317(6):635-636.DOI:10.1001/jama.2016.20563.

[58]Klebanoff MJ,Corey KE,Chhatwal J,et al.Bariatric surgery for nonalcoholic steatohepatitis:A clinical and cost-effectiveness analysis[J].Hepatology,2017,65(4):1156-1164.DOI:10.1002/hep.28958.

[59]中华医学会感染病学分会,肝脏炎症及其防治专家共识委员会.肝脏炎症及其防治专家共识[J].中华肝脏病杂志,2014,22(2):94-103.DOI:10.3760/cma.j.issn.1007-3418.2014.02.006.Chinese Society of Infectious Diseases,Chinese Medical Association,Expert Committee for Prevention and Management of Liver Inflammation.Prevention and management of liver inflammation:an expert consensus in China[J].Chin J Hepatol,2014,22(2):94-103.DOI:10.3760/cma.j.issn.1007-3418.2014.02.006.

[61]Neuschwander-Tetri BA,Loomba R,Sanyal AJ,et al.Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic,non-alcoholic steatohepatitis(FLINT):a multicentre,randomised,placebo-controlled trial[J].Lancet,2015,385(9972):956-965.DOI:10.1016/S0140-6736(14)61933-4.

[62]Han Y,Shi JP,Ma AL,et al.Randomized,vitamin E-controlled trial of bicyclol plus metformin in non-alcoholic fatty liver disease patients with impaired fasting glucose[J].Clin Drug Investig,2014,34(1):1-7.DOI:10.1007/s40261-013-0136-3.

[63]Wah Kheong C,Nik Mustapha NR,Mahadeva S.A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis[J].Clin Gastroenterol Hepatol,2017,15(12):1940-1949.DOI:10.1016/j.cgh.2017.04.016.

[64]Newsome PN,Allison ME,Andrews PA,et al.Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis[J].Gut,2012,61(4):484-500.DOI:10.1136/gutjnl-2011-300886.

[65]Pais R,Barritt AS 4th,Calmus Y,et al.NAFLD and liver transplantation:Current burden and expected challenges[J].JHepatol,2016,65(6):1245-1257.DOI:10.1016/j.jhep.2016.07.033.

[66]Ajmera VH,Terrault NA,Harrison SA.Is moderate alcohol use in nonalcoholic fatty liver disease good or bad?A critical review[J].Hepatology,2017,65(6):2090-2099.DOI:10.1002/hep.29055.